

**AMENDMENTS TO THE CLAIMS**

Please cancel Claims 1-26 without prejudice and insert therefor new Claims 27-34. This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-26 (canceled)

27. (new) A pharmaceutical composition comprising a selective COX-2 inhibitor and an NK-1 receptor antagonist, together with at least one pharmaceutically acceptable carrier or excipient.

28. (new) The method of Claim 27 wherein the NK-1 receptor antagonist is orally active and CNS-penetrant.

29. (new) A method for the treatment of an inflammatory disorder, which method comprises administration to a patient in need thereof of an amount of a selective COX-2 inhibitor and an amount of an NK-1 receptor antagonist, such that together they give effective relief.

30. (new) The method of Claim 29 wherein the inflammatory disorder is selected from rheumatoid arthritis, degenerative joint disease, osteoarthritis, bursitis, tendinitis, ankylosing spondylitis, gout and synovitis.

31. (new) The method of Claim 29 wherein the NK-1 receptor antagonist is orally active and CNS-penetrant.

32. (new) A method for the prevention of an inflammatory disorder, which method comprises administration to a patient in need thereof of an amount of a selective COX-2 inhibitor and an amount of an NK-1 receptor antagonist, such that together they give effective relief.

33. (new) The method of Claim 32 wherein the inflammatory disorder is selected from rheumatoid arthritis, degenerative joint disease, osteoarthritis, bursitis, tendinitis, ankylosing spondylitis, gout and synovitis.

34. (new) The method of Claim 32 wherein the NK-1 receptor antagonist is orally active and CNS-penetrant.